Twelve More Years
In a story that is perhaps related to the nexus between certain companies and certain Congressfolk, Ted Kennedy has proposed doubling patent exclusivity for at least some biotech drugs. Here is the story:
It is perhaps interesting to speculate whether this is part of wider negotiations, which seems likely, or something else. Personally, I have favored extending exclusivity for drugs that require an unusually arduous approval process and/as a kind of "reward" for superlative regulatory compliance, particularly in the arenas responsible completion of phase IV studies and responsible promotion.
Kennedy's proposal is so out of synch with what the administration has proposed that it will be "interesting" to see where the middle turns out to be.